首页 联合治疗(usUTHR)-基本信息

联合治疗(usUTHR)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:203.34

最高价:205.52

成交量:403191.0

昨收价:201.67

最低价:200.94

最新价:203.73

行情图标
概要信息

中文名称:联合治疗


英文名称:United Therapeutics


行业:医疗


简介:United Therapeutics Corporation于1996年成立于特拉华


电话:1-301-6089292


最新量化综合结论
百科信息
  • 相关网站
  • 员工交易记录
  • 持股信息
  • 领导人信息

交易日期 交易人 职位 类型 交易份额 价格
2019-06-26 Dwek (Raymond) Director Sell 3750 76.11
2019-06-25 Thompson (Tommy G) Director Buy 1870 --
2019-06-25 Olian Judy D Director Buy 1870 --
2019-06-25 Kurzweil (Raymond) Director Buy 1870 --
2019-06-25 Giltner (Richard A) Director Buy 3750 --
2019-06-25 Dwek (Raymond) Director Buy 3750 --
2019-06-25 Sullivan (Louis W) Director Buy 3750 --
2019-06-19 Giltner (Richard A) Director Sell 5000 79.05
2019-06-19 Giltner (Richard A) Director Buy 5000 41.14
2019-06-12 Giltner (Richard A) Director Sell 5000 80.29
2019-06-12 Giltner (Richard A) Director Buy 5000 41.14
2019-06-05 Giltner (Richard A) Director Sell 5000 83.22
2019-06-05 Giltner (Richard A) Director Buy 5000 41.14
2019-05-29 Giltner (Richard A) Director Buy 5000 41.14
2019-05-29 Giltner (Richard A) Director Sell 5000 86.90
2019-04-04 Giltner (Richard A) Director Sell 5000 119.45
2019-04-04 Giltner (Richard A) Director Buy 5000 41.14
2019-04-03 Causey (Christopher) Director Buy 750 63.90
2019-04-03 Causey (Christopher) Director Sell 750 118.49
2019-03-20 Mahon (Paul A) General Counsel Sell 5500 122.99
2019-03-20 Mahon (Paul A) General Counsel Buy 5500 94.96
2019-03-20 Mahon (Paul A) General Counsel Buy 500 65.80
2019-03-20 Mahon (Paul A) General Counsel Sell 500 122.99
2019-03-19 Patusky (Christopher) Director Buy 5000 54.77
2019-03-19 Patusky (Christopher) Director Sell 5000 121.24

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Apg All Pensions Group 771600 1.76% -597200 -43.63% 2019-03-31
Renaissance Technologies Corp 2241778 5.12% 45000 2.05% 2019-03-31
Fidelity Management & Research Company 2347119 5.35% -799028 -25.40% 2019-07-31
AQR Capital Management LLC 2489218 5.68% -25345 -1.01% 2019-03-31
Fidelity Management and Research Company 2640003 6.03% -184421 -6.53% 2019-03-31
FMR Inc 2688703 6.14% -181821 -6.33% 2019-03-31
BlackRock Fund Advisors 2711113 6.18% -405083 -13.00% 2019-07-31
Vanguard Group Inc 3955321 9.03% 48042 1.23% 2019-03-31
BlackRock Inc 4994759 11.40% 52760 1.07% 2019-03-31
State Street Corporation 2221938 5.07% 265561 13.57% 2019-03-31
Palo Alto Investors, LLC 1632025 3.73% -- -- 2019-03-31
First Trust Advisors L.P. 1290590 2.95% 93786 7.84% 2019-03-31
APG Asset Management 771600 1.76% -597200 -43.63% 2019-03-31
Dimensional Fund Advisors LP 813199 1.85% -26870 -3.20% 2019-07-31
Goldman Sachs Group Inc 819393 1.87% -100472 -10.92% 2019-03-31
SSGA Funds Management Inc 864534 1.97% -33299 -3.71% 2019-07-31
Acadian Asset Management LLC 1023831 2.34% 826820 419.68% 2019-03-31
Dimensional Fund Advisors, Inc. 1074843 2.45% -14139 -1.30% 2019-03-31
Vanguard Investments Australia Ltd 1161818 2.65% -16789 -1.42% 2019-07-31
Consonance Capital Management LP 1225387 2.80% 124790 11.34% 2019-03-31
Geode Capital Management, LLC 1191230 2.72% 606478 103.72% 2018-12-31
BlackRock Asset Management Canada Ltd 5156575 11.77% -261 -0.01% 2019-05-31
LSV Asset Management 616549 1.41% 106460 20.87% 2018-12-31
Merian Global Investors (UK) Limited 712970 1.63% -159218 -18.26% 2019-02-28
Robeco Institutional Asset Mgmt BV 650634 1.49% 130098 24.99% 2018-09-30
Federated Equity Mgmt Co. Of Penn 839810 1.93% 821951 4602.45% 2018-12-31
Skandinaviska Enskilda Banken AB 796126 1.83% -44497 -5.29% 2018-06-30
SEB Investment Management AB 796126 1.83% -44497 -5.29% 2018-06-30
Goldman, Sachs & Co. 1060389 2.43% 198127 22.98% 2018-09-30
BlackRock Institutional Trust Company NA 1621394 3.72% -2608 -0.16% 2018-06-30
State Street Corp 1994004 4.58% -100423 -4.79% 2018-06-30
Old Mutual Global Investors (UK) Limited 823301 1.93% 126991 18.24% 2017-12-31
Old Mutual Asset Managers UK Ltd 790459 1.81% -171440 -17.82% 2018-06-30
Thompson, Siegel & Walmsley LLC 559107 1.28% 527848 1688.63% 2018-06-30
Schroder Investment Management Group 664598 1.50% 283921 74.58% 2018-06-30
Krensavage Asset Management, LLC 552019 1.27% -101768 -15.57% 2018-06-30
State Street Global Markets, LLC 502623 1.15% -4454 -0.88% 2018-07-31
Fidelity International Ltd 643447 1.48% 1772 0.28% 2018-03-31
J.P. Morgan Securities Inc 665423 1.53% 231904 53.49% 2018-03-31
NORGES BANK 453761 1.05% 111808 32.70% 2017-12-31
D. E. Shaw & Co LP 601140 1.39% 46063 8.30% 2017-12-31
Wells Fargo & Co 717474 1.66% 13898 1.98% 2017-12-31
Scopia Management Inc. 3248869 7.56% 3248869 -- 2016-12-31
FIL Investment Services (UK) Ltd 451167 1.06% 127355 39.33% 2017-12-31
Quantitative Management Associates LLC 526194 1.21% 165808 46.01% 2017-06-30
Morgan Stanley & Co Inc 527825 1.22% -325717 -38.16% 2017-06-30
Scopia Management Inc 4092701 9.59% -208651 -4.85% 2016-09-30
ARONSON+JOHNSON+ORTIZ 2091565 4.90% -49976 -2.33% 2016-09-30
Northern Trust Investments N A 478835 1.12% -18315 -3.68% 2016-09-30
Scopia Capital ManagementLP 2957490 4.00% 545479456 0.10% 1999-11-30
The Vanguard Group 3010930 4.00% 555335929 0.10% 1999-11-30
FMR,LLC 3960701 4.00% 730511692 0.10% 1999-11-30
Martine Rothblatt 3975609 4.00% 733261324 0.10% 1999-11-30
BlackRock,Inc. 6727255 4.00% 1240774912 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Principal MidCap S&P 400 Index SP 156776 0.36% 1404 0.90% 2019-06-30
iShares Core S&P Mid-Cap ETF 1285273 2.93% 2480 0.19% 2019-07-30
First Trust NYSE Arca Biotech Fund 1268427 2.89% -3056 -0.24% 2019-07-31
Vanguard Total Stock Market Index Fund 1151358 2.63% 215 0.02% 2019-06-30
Vanguard Small Cap Index 1117390 2.55% 36076 3.34% 2019-06-30
Vanguard Small Cap Value Index Fund 695058 1.59% 12192 1.79% 2019-06-30
Vanguard Extended Market Index Fund 602085 1.37% -1590 -0.26% 2019-06-30
SPDR 498883 1.14% -2975 -0.59% 2019-06-30
iShares Nasdaq Biotechnology ETF 432481 0.99% 4552 1.06% 2019-07-30
iShares S&P Mid-Cap 400 Value ETF 338278 0.77% -- -- 2019-07-30
Fidelity Northstar Fund 310000 0.71% -5000 -1.59% 2019-03-31
DFA US Targeted Value Portfolio 167193 0.38% -- -- 2019-05-31
State Street Russell Small/Mid Cap 185785 0.42% -- -- 2019-06-30
DFA US Core Equity II Fund 191881 0.44% -- -- 2019-05-31
Fidelity 209615 0.48% -3196 -1.50% 2019-06-30
Pictet Biopharmaceutical Mother 210900 0.48% 115489 121.04% 2019-04-15
State Street S&P Mid Cap Index Fund 269655 0.61% -- -- 2019-06-30
Transamerica Mid Cap Value Opportunities 279600 0.64% 87000 45.17% 2019-06-30
DFA US Large Cap Value Portfolio 165942 0.38% -110 -0.07% 2019-05-31
First Trust Health Care AlphaDEX 231750 0.53% -- -- 2019-06-30
iShares Core MSCI AllCntry Wld exCan ETF 1274108 2.91% -- -- 2019-05-23
iShares S&P US Mid-Cap ETF (CAD-Hedged) 1273612 2.91% -- -- 2019-05-30
iShares S&P US Mid-Cap ETF 1273612 2.91% -- -- 2019-05-30
iShares Core S&P US Total Market ETF 1273612 2.91% -- -- 2019-05-30
Vanguard Small Cap Index Fund 1083904 2.47% 8236 0.77% 2019-04-30
AST Prudential Growth Allocation Port 178600 0.41% 10700 6.37% 2019-03-31
Merian Global Equity Absolute Return Fd 518299 1.19% -99584 -16.12% 2018-06-30
Fidelity America Fund 368169 0.84% -25 -0.01% 2019-02-28
CLI Fidelity American 368194 0.84% 37174 11.23% 2019-01-31
Old Mutual Global Eq Abs Ret Fund 518299 1.19% -99584 -16.12% 2018-06-30
AQR Long-Short Equity Fund 159125 0.37% 15626 10.89% 2018-09-30
SEB L 205800 0.47% -- -- 2018-11-30
Federated Kaufmann Small Cap Fund 822570 1.89% 822570 -- 2018-09-30
iShares S&P Mid-Cap 400 Growth ETF 264809 0.61% -1135 -0.43% 2018-11-30
AQR Style Premia Alternative Fund 213906 0.49% 213906 -- 2017-09-30
American Beacon Bridgeway Lrg Cap Val Fd 247200 0.57% -- -- 2017-12-31
Vanguard Total Stock Mkt Idx 1039661 2.39% 1058 0.10% 2018-07-31
Vanguard Small Cap Value Index Inv 654177 1.50% 6841 1.06% 2018-07-31
First Trust NYSE Arca Biotech ETF 594383 1.38% -- -- 2018-09-13
Vanguard Extended Market Idx Inv 574653 1.32% 3590 0.63% 2018-07-31
iShares Nasdaq Biotechnology 493776 1.14% -939 -0.19% 2018-09-12
iShares S&P Mid-Cap 400 Growth 269275 0.62% 2660 1.00% 2018-09-12
Fidelity Spartan 197225 0.45% 4146 2.15% 2018-07-31
AQR Style Premia Alternative I 213906 0.50% 213906 -- 2017-09-30
DFA US Core Equity 2 I 191881 0.44% -- -- 2018-07-31
DFA US Large Cap Value I 177055 0.41% 228 0.13% 2018-07-31
State Street Russell Small/Mid Cap Idx Fd Cl I 148363 0.34% 2300 1.57% 2017-06-30
Transamerica Mid Cap Value Opps A 149800 0.34% -- -- 2018-07-31
Fidelity VIP Mid Cap Inv 220800 0.51% -40100 -15.37% 2018-06-30
PowerShares Dynamic Pharmaceuticals ETF 134933 0.34% -- -- 2018-07-12
American Beacon Bridgeway Lg Cp Val Inst 247200 0.57% -- -- 2017-12-31
Vanguard Global Equity Inv 129432 0.30% 23097 21.72% 2017-12-31
iShares Russell 1000 Value 139035 0.37% 189 0.14% 2017-12-28
Fidelity Advisor 150500 0.35% -3400 -2.21% 2016-12-31
CREF Stock R1 143276 0.34% -4088 -2.77% 2016-12-31
Glenmede Large Cap Growth 131397 0.31% -- -- 2016-12-31
Fidelity® Select Biotechnology Portfolio 995809 2.20% -- -- 2015-09-30
iShares Core S&P Mid-Cap (AU) 793618 1.80% 1070 0.10% 2015-11-19
BlackRock Capital Appreciation Fund 676374 1.50% -6431 -0.90% 2015-10-31
First Eagle Fund of America 546585 1.20% 96805 21.50% 2015-08-31
Vanguard Small Cap Growth Index Fund 521123 1.10% -13244 -2.50% 2015-10-31
SPDR® S&P MIDCAP 400 ETF 466314 1.00% 21261 4.80% 2015-10-31
Laudus US Large Cap Growth Fund 437185 1.00% 7755 1.80% 2015-09-30
T. Rowe Price Health Sciences Fund 412293 0.90% -101150 -19.70% 2015-09-30
Metropolitan Ser BlackRock Cap Apprec Pt 372536 0.80% -12380 -3.20% 2015-09-30
Fidelity® Ser Intrinsic Opportunities Fd 1250000 2.70% -- -- 2015-07-31

Raymond C. Kurzweil Founder of FatKat, Inc., Kurzweil Technologies, Inc., Medical Learning Co., Inc. and Singularity Education Group, Raymond C. Kurzweil is Chairman & Chief Executive Officer of Kurzweil Technologies, Inc., Chairman & Chief Executive Officer at Medical Learning Co., Inc. and President of FatKat, Inc. Dr. Kurzweil is also on the board of United Therapeutics Corp., X PRIZE Foundation and Singularity Education Group. In his past career Raymond C. Kurzweil was Engineering Director at Google LLC. He received an undergraduate degree from Massachusetts Institute of Technology, a doctorate from Rensselaer Polytechnic Institute and a doctorate from Hofstra University.
Martine A. Rothblatt Martine A. Rothblatt founded United Therapeutics Corp., SIRIUS Satellite Radio, Inc. and Lung Biotechnology PBC. Currently, Dr. Rothblatt is Chairman & Chief Executive Officer of United Therapeutics Corp. and President & Chief Executive Officer at Lung Biotechnology PBC (a subsidiary of United Therapeutics Corp.). Martine A. Rothblatt is also on the board of The Kennedy Center Corporate Fund and United Therapeutics Europe Ltd. Dr. Rothblatt previously occupied the position of Chairman & Chief Executive Officer for SIRIUS Satellite Radio, Inc. Dr. Rothblatt received an MBA and a graduate degree from the University of California, Los Angeles and a doctorate from the University of London.
Tommy George Thompson Mr. Tommy G. Thompson is a Chairman at Vital Decisions LLC, a Chairman-Trustees Board at Physicians Realty Trust, a Chairman at TherapeuticsMD, Inc., an Independent Director at United Therapeutics Corp., an Independent Director at Centene Corp., a Chairman & Chief Executive Officer at Thompson Holdings, Inc., a Member at State Bar of Wisconsin, a Member at The District of Columbia Bar and an Operating Partner at Windrose Health Investors LLC. He is on the Board of Directors at Tyme Technologies, Inc., United Therapeutics Corp., Centene Corp., Accordia Global Health Foundation, Armada Media Corp., Cleveland HeartLab, Inc. and Medical Missions For Children, Inc. Mr. Thompson was previously employed as a Chairman by Stayhealthy, Inc., an Independent Director by Cytori Therapeutics, Inc., an Independent Director by Cancer Genetics, Inc., a Chairman by AGA Medical Holdings, Inc., an Independent Director by C.R. Bard, Inc. (New Jersey), a Chairman by AGA Medical Corp., a Chairman by CareView Communications, Inc., a Senior Partner by Akin, Gump, Strauss, Hauer & Feld LLP, an Independent Chairman by The Deloitte Center for Health Solutions, a Chairman by Logistics Health, Inc., a Chairman by The Global Fund to Fight AIDS, Tuberculosis & Malaria, a Secretary & Governor by US Department of Health & Human Services (DC), a Governor by State of Wisconsin, a Venture Partner by Burrill & Co. LLC, a Chairman by Education Commission of the States, a Chairman by Midwestern Governors Conference, and a Chairman by National Governors Association. He also served on the board at Tyme, Inc., Tenex Health, Inc., CNS Response, Inc., SpectraScience, Inc., Medco Health Solutions, Inc., PURE Bioscience, Inc., VeriChip Corp., Harmony Information Systems, Inc., Picis, Inc., ProCure Treatment Centers, Inc., Voyager Pharmaceutical Corp. and X-Shares Advisors LLC. He received his undergraduate degree from the University of Wisconsin and a graduate degree from the University of Wisconsin.
Judy D. Olian Judy D. Olian is President of Quinnipiac University and Dean at UCLA Anderson School of Management and on the board of 6 other companies. In the past Dr. Olian held the position of Chairman at Association to Advance Collegiate Schools of Business and Professor at Smeal College of business. Dr. Olian received an undergraduate degree from The Hebrew University of Jerusalem and a doctorate and a graduate degree from the University of Wisconsin.
Katherine J. Klein Katherine J. Klein is on the board of United Therapeutics Corp. In her past career she occupied the position of Professor at The Wharton School of the University of Pennsylvania. She received an undergraduate degree from Yale University and a doctorate from The University of Texas.
James Christopher Edgemond Currently, James Christopher Edgemond is CFO, Treasurer & Principal Accounting Officer at United Therapeutics Corp. Mr. Edgemond is also on the board of United Therapeutics Europe Ltd. In his past career Mr. Edgemond held the position of Senior Manager at KPMG Peat Marwick LLP and Treasurer, Corporate Controller & Vice President at Clark Construction Group LLC.
Louis Wade Sullivan Louis Wade Sullivan is a businessperson who founded Medical Education for South African Blacks and who has been at the head of 7 different companies. Presently, he is Chairman at Public Broadcasting Atlanta and Chairman & Chief Executive Officer of The Sullivan Alliance. He is also on the board of United Therapeutics Corp., Emergent BioSolutions, Inc. and America's Public Television Stations and President-Emeritus at Morehouse School of Medicine. Dr. Sullivan previously was Non-Executive Chairman at ANI Pharmaceuticals, Inc., Co-Director-Hematology Division at Boston University Medical Center Hospital, Secretary at US Department of Health & Human Services (DC), Chairman of Medical Education for South African Blacks, Chairman for The National Health Museum, President of Morehouse School of Medicine, Member-National Executive Council at Boy Scouts of America, Assistant Professor at Seton Hall University and Professor at Boston University School of Medicine. Dr. Sullivan received an undergraduate degree from Morehouse College and a doctorate from Boston University School of Medicine.
Paul A. Mahon Presently, Paul A. Mahon holds the position of Secretary, Executive VP & General Counsel at United Therapeutics Corp. and Co-Managing Director at Unither Therapeutik GmbH (a subsidiary of United Therapeutics Corp.).
Raymond Allen Dwek Raymond Allen Dwek is on the board of United Therapeutics Corp. and Oxford Glycobiology Institute and Professor Emeritus at the University of Oxford. Mr. Dwek previously held the position of Chairman-Technology & Society at The Library of Congress (District of Columbia), Director & Scientific Founder at Oxford GlycoSciences Plc and President at Institute of Biology.
Christopher Patusky Christopher Patusky is on the board of United Therapeutics Corp. and Executive Manager at Slater Run Vineyards LLC and Founding Principal at Patusky Associates LLC. In the past he held the position of Director-Real Estate at The Maryland Department of Transportation. He received a graduate degree from Harvard Law School and a graduate degree from the University of Pennsylvania.
Christopher Causey Founder of Causey & Co., Christopher Causey currently is Principal at this company. Mr. Causey is also on the board of United Therapeutics Corp. In the past Mr. Causey occupied the position of Chief Marketing Officer of Definity Health Corp.
Richard Giltner Richard Giltner is on the board of United Therapeutics Corp. In his past career he occupied the position of Managing Director at Soci�0�1�0�8t�0�1�0�8 G�0�1�0�8n�0�1�0�8rale Asset Management (UK) Ltd. and Portfolio Manager at Lyxor Asset Management, Inc. He received an undergraduate degree from Northwestern University.
Michael Ian Benkowitz Michael Ian Benkowitz is on the board of United Therapeutics Europe Ltd. and President & Chief Operating Officer of United Therapeutics Corp.
Nilda Mesa Nilda Mesa is on the board of United Therapeutics Corp. and Director-Urban Sustainability at Columbia University. Ms. Mesa received an undergraduate degree from Harvard Law School and an undergraduate degree from Northwestern University.

量化对比

全部评论 5

  • 德展健康:子公司东方略于近日收到中国人类遗传资源管理办公室的正式批件,同意东方略开展VGX-3100与器械CELLECTRATM5PSP联合治疗HPV-16和/或HPV-18相关宫颈高度鳞状上皮内病变(HSIL)的三期临床试验。

  • 【德展健康:VGX-3100项目三期试验达到临床疗效的主要终点和所有次要终点】德展健康公告,公司于2021年3月3日收到公司子公司东方略的告知函,东方略的美国合作方Inovio公司宣布了其与东方略联合研发的一项DNA治疗药物VGX-3100与器械CELLECTRATM5PSP联合治疗HPV-16/18相关宫颈高度鳞状上皮内病变(HSIL)的首个III期临床试验(REVEAL1)的积极结果,在全部可评估受试者中,达到临床疗效的主要终点和所有次要终点。

  • 【恒瑞医药:氟唑帕利胶囊获美国FDA国际多中心临床试验资格】恒瑞医药公告,公司已于美国时间2021年1月21日向美国食品药品监督管理局提交了氟唑帕利胶囊国际多中心临床试验申请并获受理。日前,公司已获得美国FDA国际多中心临床试验资格,并将于近期开展相关临床试验。除用于铂敏感的复发性卵巢癌、输卵管癌或原发性腹膜癌治疗外,氟唑帕利胶囊单药或联合甲磺酸阿帕替尼片的多个适应症开发已处在III期临床研究阶段,另有多种联合治疗方案,包括与阿比特龙联合、与抗PD-L1抗体SHR-1316联合、以及与替莫唑胺联合治疗多种实体肿瘤已处于临床开发阶段。

  • 【泽璟制药:多纳非尼获得药物临床试验批准通知书】泽璟制药公告,公司于近日收到国家药监局核准签发的《药物临床试验批准通知书》。本次获批开展甲苯磺酸多纳非尼片与KN046注射液联合治疗晚期消化道实体瘤的临床试验。甲苯磺酸多纳非尼片是公司开发的口服多靶点、多激酶抑制剂类小分子抗肿瘤药物,属于1类新药,公司拥有独立的自主知识产权。

  • 【泽璟制药:多纳非尼获得药物临床试验批准通知书】泽璟制药公告,公司于近日收到国家药监局核准签发的《药物临床试验批准通知书》。本次获批开展甲苯磺酸多纳非尼片与KN046注射液联合治疗晚期消化道实体瘤的临床试验。甲苯磺酸多纳非尼片是公司开发的口服多靶点、多激酶抑制剂类小分子抗肿瘤药物,属于1类新药,公司拥有独立的自主知识产权。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐